Tesla, U.K. government rumored to be working on factory, Electrek says » 11:3206/0306/03/20
A rumor is circulating…
Administration to ban Chinese passenger carriers from U.S. flights, Reuters says » 09:5106/0306/03/20
SPY, SPX, ALK, LUV, DAL, JBLU, UAL, SAVE, AAL
The Trump administration…
The Trump administration plans to announce plans Wednesday to ban Chinese passenger carriers from flying to the United States starting in mid-June, according to Reuters, citing officials briefed on the matter. The White House and Department of Transportation denied comment to Reuters on the matter. Restrictions are expected to take effect June 16, but could be moved up, the people briefed on the matter told Reuters. The report notes that Delta (DAL) and United (UAL) have asked to resume flights to China this month and that Chinese carriers have continued U.S. flights during the pandemic. Other publicly traded U.S. air carriers include Alaska Air (ALK), American Airlines (AAL), JetBlue (JBLU), Southwest (LUV) and Spirit Airlines (SAVE). Reference Link
Tesla employee tests positive for COVID-19 at Buffalo factory, The Verge says » 09:4106/0306/03/20
A Tesla (TSLA) employee…
Tesla worker tests positive for COVID-19 at NY facility, The Verge says » 17:3606/0206/02/20
According to internal…
According to internal Tesla emails obtained by The Verge, "a Panasonic employee at Tesla's solar panel factory in Buffalo, New York," tested positive in March for COVID-19, writes Sean O'Kane of The Verge. According to The Verge, it is the fourth known Tesla facility employee to test positive for the virus "following one at the Gigafactory in Nevada, and two office workers in California." "The infected employee was not in the office after March 17th, according to the emails, which a current employee provided to The Verge on the condition of anonymity," added The Verge. Reference Link
Digital Ally launches non-contact thermometer, sanitizer in response to pandemic » 09:5606/0206/02/20
Digital Ally announced…
Digital Ally announced the launch of two product lines "in direct response to the increased safety precautions organizations and individuals are taking due to the Covid-19 pandemic." ThermoVu is a non-contact temperature-measuring instrument that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined parameters, Digital Ally said. The company is also launching its Shield disinfectant/sanitizer and several related products to "fulfill demand by current customers and others for a disinfectant and sanitizer that is less harsh than many of the traditional products now widely distributed," the company added.
Digital Ally 3.1M share Secondary priced at $1.65 » 09:1806/0206/02/20
Aegis acted as sole book…
Aegis acted as sole book running manager for the offering.
Notable open interest changes for June 2nd » 08:5506/0206/02/20
ECL, PFE, TSLA, ZM
Monday's total option volume of 21.1 million contracts resulted in net open interest growth of 3.71 million calls and 2.85 million puts. Ecolab (ECL), Pfizer (PFE), Tesla (TSLA) and Zoom Video Communications (ZM) saw the greatest growth. Top five new positions opened include 86k Ecolab (ECL) 6/12 weekly 290 calls, 85k Ecolab (ECL) 6/12 weekly 290 puts, 47k Ecolab (ECL) 6/5 weekly 275 calls, 47k Ecolab (ECL) 6/5 weekly 275 puts and 26k Apergy (APY) Jun-20 15 puts.
Menlo Therapeutics announces results from Phase 2 trial of FCD105 » 08:0206/0206/02/20
Menlo Therapeutics announced positive results from a Phase 2 clinical trial evaluating the preliminary safety and efficacy of FCD105, the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. Study FX2016-40 enrolled 447 patients in the United States who were randomized to either FCD105 foam, 3% minocycline foam, 0.3% adapalene foam, or vehicle foam. The Company has begun preparations to conduct an End of Phase 2 meeting with the FDA before the end of this year. FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of Investigator's Global Assessment treatment success and absolute change from baseline in mean inflammatory counts at Week 12. The proportion of patients achieving IGA treatment success in the FCD105 treatment group was 35.9% compared to 15.7% of patients in the vehicle treatment group. Absolute reduction in inflammatory lesion counts at Week 12 was -19.4 for the FCD105 treatment group compared to -15.58 for the vehicle treatment group. The trial was not originally powered to demonstrate a statistical difference between FCD105 and either 3% minocycline foam or 0.3% adapalene foam treatments; however, the majority of these comparisons did show a statistically significant improvement of FCD105 at Week 12. Numerical improvement was observed for FCD105 on all efficacy endpoints for these comparisons at Week 12. Absolute reduction in non-inflammatory lesion counts at Week 12 was also assessed with a mean lesion count reduction of -24.94 for the FCD105 treatment group compared to -22.87 for the vehicle treatment group. Although numerical improvement was shown, this was not statistically significant, which has been attributed to outlier results affecting both FCD105 and vehicle treatment groups. Conversely, absolute reduction in non-inflammatory lesion counts at Week 12 for FCD105 did show a statistically significant improvement compared to each of 3% minocycline foam and 0.3% adapalene foam. The most commonly reported treatment-emergent adverse event in the trial was upper respiratory tract infection with dry skin being the most commonly reported cutaneous adverse event. The majority of adverse events were assessed as mild in severity. There were no serious adverse events. FCD105 was comparably tolerated to vehicle in all local skin tolerability assessments with 93% or greater of severity scores being assessed as "none" or "mild" for burning/stinging, itching, dryness, scaling, erythema and hyperpigmentation.
Cities continue to vie for new Tesla Cybertruck Gigafactory, Bloomberg reports » 07:0006/0206/02/20
Even with less money…
Even with less money coming in due to the COVID-19 pandemic lockdowns, cities in middle America are bidding to be the home of Tesla's new Cybertruck Gigafactory, Mya Frazier of Bloomberg reports. Despite shrinking budgets and drops in tax revenue, cities are attempting to lure large companies like Tesla with billion dollar incentive packages. While questions remain on the justification of these bids, cities reportedly believe the long-term economic benefits will outweigh the cost. Even though cities like Joplin, Missouri had made public its bid to the electric automaker, cities like Tulsa, Oklahoma and Austin, Texas are considered finalists, while keeping their incentive packages a secret. Reference Link
Digital Ally files to sell common stock, no amount given » 18:5006/0106/01/20
Aegis Capital Corp. is…
Aegis Capital Corp. is acting as the sole book-running manager for the offering.